11:33:19 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-05-15 Årsstämma 2024
2024-04-25 Bokslutskommuniké 2023
2023-10-11 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma 2023
2023-04-28 Bokslutskommuniké 2022
2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 Ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa.
2023-09-29 08:30:00

COMPANY ANNOUNCEMENT

Copenhagen, Denmark, September  29, 2023 - Brain+ A/S (Nasdaq First North: BRAINP)

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
  • The exercise price of the TO 2 warrants has been set at DKK 0.20
  • The exercise period for the TO 2 warrants runs from 2-16 October 2023
  • The TO 2 warrants are tradable with the last day of trading set to 12 October 2023

Brain+ A/S ("Brain+" or "the Company") completed a pre-emptive rights issue of units during the second quarter of 2023. As part of the issue, a total of 28,582,348 warrants of series TO 2 were issued. Each warrant gives the holder the right to subscribe for one (1) new share in the Company. The exercise price for warrants of series TO 2 was to be determined to 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during the calculation period from 1 September up to and including 28 September 2023, however not lower than DKK 0.20 and not higher than DKK 0.80. During the calculation period, the volume-weighted average price of the Company's share was approximately DKK 0.27, therefore the exercise price of warrants of series TO 2 has been set to DKK 0.20. The exercise period of warrants of series TO 2 runs from 2 October 2023 up to and including 16 October 2023.

If all warrants of series TO 2 are exercised, Brain+ will receive approximately DKK 5.7 million before transaction related costs. Proceeds from the warrant exercise are intended to fund operational activities of the Company until the next funding event.

For the warrants to not expire without value, it is required that the holder actively exercises the rights attached to the warrants to subscribe for new shares no later than 16 October 2023 or sell the warrants over the market no later than 12 October 2023. Please note that custodian banks might have different deadlines to their customers than the official exercise period.

Complete terms and conditions for the warrants of series TO 2 can be found in the prospectus approved by the Danish Financial Supervisory Authority and published by the Company on 24 April 2023. The approved prospectus as well as additional informative documents, including a FAQ summary, are available under Corporate Actions in the Investor/Announcements and financial documents' section of the Company's webpage (https://www.brain-plus.com/investor/announcements_and_financial_documents/).  The prospectus is also available on the Danish Financial Supervisory Authority's website (https://oam.finanstilsynet.dk).

Summarized terms for the warrants of series TO 2:

Exercise period: 2-16 October 2023
Exercise price: DKK 0.20
Last day of trading in 12 October 2023
warrants of series TO
2:
Issue volume: 28,542,348 warrants of series TO 2, which entitle to
a maximum subscription of 28.542,348 new shares. If
all warrants are exercised, the Company will receive
proceeds of approximately DKK 5.7 million before
issuing costs.
Dilution: Upon full exercise of warrants of series TO 2, the
number of shares of nominal value DKK 0.10 each will
increase by 28,542,348 shares from 44,262,866 shares
to 72,805,214 shares, and the Company's share capital
will increase by DKK 2,854,234.80 from DKK
4,426,286.60 to DKK 7,280,521.40. If all warrants of
series TO 2 are exercised, the dilution of the number
of shares and votes in the Company amounts to
approximately 39 percent.

Please note that warrants of series TO 2 that are not exercised no later than 16 October 2023, or not sold no later than 12 October 2023, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

How warrants are exercised (Nominee-registered warrants):
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee/custodian bank. Please contact your nominee/custodian bank directly for additional information.

Outcome
The outcome of the exercise of warrants of Series TO 2 will be published by Brain+ in a company announcement on or around 18 October 2023. Shares that have been subscribed and paid for will be delivered to the subscriber when registration of the capital increase has been completed with the Danish Companies Registration Office.

Advisors
In connection with the rights issue, Sedermera Corporate Finance AB and Gemstone Capital A/S act as financial advisors to Brain+. Markets & Corporate Law Nordic AB act as legal advisor. Nordic Issuing AB is the issuing agent.

For more information about the warrant exercise, please contact:

Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se

Gemstone Capital A/S
Phone: +45 33 22 07 00

E-mail: sh@gemstonecapital.com

www.gemstonecapital.com 

For more information about Brain+, please contact:

Kim Baden-Kristensen, CEO
Phone: +45 31393317
E-mail: kim@brain-plus.com

www.brain-plus.com

Certified Adviser

Keswick Global AG

Phone: +43 1 740 408 045

E-mail: info@keswickglobal.com